• Journal of Veterinary Clinics
• /
• v.23 no.4
• /
• pp.416-420
• /
• 2006

Compare to testing sera individually, pooled-serum testing has considered as a cost-effective method, particularly on a large population-based seroprevalence studies. This study was to determine the relationship between individual sera and pooled sera titers for detection of avian infectious bronchitis virus (IBV) and to evaluate suitability of pooled sera by comparing prevalences estimated from both samples. A total of 5,000 individual samples were collected from 500 flocks in Chungcheong, Gyunsgi, and Kangwon provinces between January 2005 and February 2006. Ten samples were randomly selected from each flock. Five-hundred pooled sera were prepared by mixing equal amount of each 10 individual serum from the original samples. IBV antibody titers were measured by hemagglutination inhibition (HI) test. The least squares regression analysis was performed to construct equation between pooled and mean individual titers. To determine whether the flock is infected 4 arbitrary criteria were used: detection of at least 1 chicken with HI titer ${\ge}$ 9 (criterion 1), detection of at least 2 samples with HI titer ${\ge}$9 (criterion 2), detection of at least 1 sample with HI titer ${\ge}$ 10 (criterion 3), and filially detection of at least 1 sample with HI titer ${\ge}$ 11 (criterion 4). The receiver operating characteristic (ROC) curve was used to examine the cut-off points of pooled titers showing optimal diagnostic accuracy. The area under the curve (AUC), sensitivities (Se), specificities (Sp), and positive (PPV) and negative (NPV) predictive values were calculated. The regression equation between pooled titers (pool) and mean individual titers (mean) was: $pool= 1.2498+0.8952{\times}mean$, with coefficient of determination of 87% (p< 0.0001). The optimal cut-off points of pooled titers were titer 8 for criterion 1 (AUC=0.975, Se=0.883, Sp=0.959, PPV=0.985, NPV=0.728), titer 8 for criterion 2 (AUC=0.969, Se=0.954, Sp=0.855, PPV=0.926, NPV=0.907), titer 9 for criterion 3 (AUC=0.970, Se=0.836, Sp=0.967, PPV=0.978, NPV=0.772), and titer 9 for criterion 4 (AUC= 0.946, Se=0.928, Sp=0.843, PPV=0.857, NPV=0.921). The difference of 'prevalence estimated by individual and pooled sample showed a minimum of 2% for criteria 2 and a maximum of 9.1:% for criteria 3. These results indicate that the use of pooled sera in HI test for screening IBV infection in laying hen flocks is considered as a cost-effective method of testing large numbers of samples with high diagnostic accuracy.

• Journal of Korean Society of Industrial and Systems Engineering
• /
• v.45 no.4
• /
• pp.53-60
• /
• 2022

In a group-testing method, instead of testing a sample, for example, blood individually, a batch of samples are pooled and tested simultaneously. If the pooled test is positive (or defective), each sample is tested individually. However, if negative (or good), the test is terminated at one pooled test because all samples in the batch are negative. This paper considers a queueing system with a two-stage group-testing policy. Samples arrive at the system according to a Poisson process. The system has a single server which starts a two-stage group test in a batch whenever the number of samples in the system reaches exactly a predetermined size. In the first stage, samples are pooled and tested simultaneously. If the pooled test is negative, the test is terminated. However, if positive, the samples are divided into two equally sized subgroups and each subgroup is applied to a group test in the second stage, respectively. The server performs pooled tests and individual tests sequentially. The testing time of a sample and a batch follow general distributions, respectively. In this paper, we derive the steady-state probability generating function of the system size at an arbitrary time, applying a bulk queuing model. In addition, we present queuing performance metrics such as the offered load, output rate, allowable input rate, and mean waiting time. In numerical examples with various prevalence rates, we show that the second-stage group-testing system can be more efficient than a one-stage group-testing system or an individual-testing system in terms of the allowable input rates and the waiting time. The two-stage group-testing system considered in this paper is very simple, so it is expected to be applicable in the field of COVID-19.

• Journal of Pharmaceutical Investigation
• /
• v.30 no.3
• /
• pp.191-199
• /
• 2000

Genomics is providing targets faster than we can validate them and combinatorial chemistry is providing new chemical entities faster than we can screen them. Historically, the drug discovery cascade has been established as a sequential process initiated with a potency screening against a selected biological target. In this sequential process, pharmacokinetics was often regarded as a low-throughput activity. Typically, limited pharmacokinetics studies would be conducted prior to acceptance of a compound for safety evaluation and, as a result, compounds often failed to reach a clinical testing due to unfavorable pharmacokinetic characteristics. A new paradigm in drug discovery has emerged in which the entire sample collection is rapidly screened using robotized high-throughput assays at the outset of the program. Higher-throughput pharmacokinetics (HTPK) is being achieved through introduction of new techniques, including automation for sample preparation and new experimental approaches. A number of in vitro and in vivo methods are being developed for the HTPK. In vitro studies, in which many cell lines are used to screen absorption and metabolism, are generally faster than in vivo screening, and, in this sense, in vitro screening is often considered as a real HTPK. Despite the elegance of the in vitro models, however, in vivo screenings are always essential for the final confirmation. Among these in vivo methods, cassette dosing technique, is believed the methods that is applicable in the screening of pharmacokinetics of many compounds at a time. The widespread use of liquid chromatography (LC) interfaced to mass spectrometry (MS) or tandem mass spectrometry (MS/MS) allowed the feasibility of the cassette dosing technique. Another approach to increase the throughput of in vivo screening of pharmacokinetics is to reduce the number of sample analysis. Two common approaches are used for this purpose. First, samples from identical study designs but that contain different drug candidate can be pooled to produce single set of samples, thus, reducing sample to be analyzed. Second, for a single test compound, serial plasma samples can be pooled to produce a single composite sample for analysis. In this review, we validated the issue whether the second method can be applied to practical screening of in vivo pharmacokinetics using data from seven of our previous bioequivalence studies. For a given drug, equally spaced serial plasma samples were pooled to achieve a 'Pooled Concentration' for the drug. An area under the plasma drug concentration-time curve (AUC) was then calculated theoretically using the pooled concentration and the predicted AUC value was statistically compared with the traditionally calculated AUC value. The comparison revealed that the sample pooling method generated reasonably accurate AUC values when compared with those obtained by the traditional approach. It is especially noteworthy that the accuracy was obtained by the analysis of only one sample instead of analyses of a number of samples that necessitates a significant man-power and time. Thus, we propose the sample pooling method as an alternative to in vivo pharmacokinetic approach in the selection potential lead(s) from combinatorial libraries.

• The Korean Journal of Applied Statistics
• /
• v.21 no.1
• /
• pp.177-182
• /
• 2008

There are times when we need more sample to achieve a more accurate estimator. Since these two sets of sample have the information about the same population, it is necessary to treat both as a single combined data. In this paper we present the unpooled sample variance for the combined data when we just know a sample mean and variance for the each data set without the raw data. It is shown that the pooled variance $s^2_p$ is always greater than the exact variance $s^2_t$ when ${\bar{x}}_n\;=\;{\bar{y}}_m$. And the difference of means for two data, ${\bar{x}}_n-{\bar{y}}_m}$, is larger, the difference of $s^2_p$ and $s^2_t$ is larger.

• The Korean Journal of Applied Statistics
• /
• v.22 no.1
• /
• pp.129-140
• /
• 2009

In this paper, we consider simultaneous confidence intervals for the difference of proportions between two groups taken from multivariate binomial distributions in a nonparametric way. We briefly discuss the construction of simultaneous confidence intervals using the method of adjusting the p-values in multiple tests. The features of bootstrap simultaneous confidence intervals using non-pooled samples are presented. We also compute confidence intervals from the adjusted p-values of multiple tests in the Westfall (1985) style based on a pooled sample. The average coverage probabilities of the bootstrap simultaneous confidence intervals are compared with those of the Bonferroni simultaneous confidence intervals and the Sidak simultaneous confidence intervals. Finally, we give an example that shows how the proposed bootstrap simultaneous confidence intervals can be utilized through data analysis.

• Journal of Korean Society of Industrial and Systems Engineering
• /
• v.44 no.4
• /
• pp.154-168
• /
• 2021

COVID-19 has been spreading all around the world, and threatening global health. In this situation, identifying and isolating infected individuals rapidly has been one of the most important measures to contain the epidemic. However, the standard diagnosis procedure with RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) is costly and time-consuming. For this reason, pooled testing for COVID-19 has been proposed from the early stage of the COVID-19 pandemic to reduce the cost and time of identifying the COVID-19 infection. For pooled testing, how many samples are tested in group is the most significant factor to the performance of the test system. When the arrivals of test requirements and the test time are stochastic, batch-service queueing models have been utilized for the analysis of pooled-testing systems. However, most of them do not consider the false-negative test results of pooled testing in their performance analysis. For the COVID-19 RT-PCR test, there is a small but certain possibility of false-negative test results, and the group-test size affects not only the time and cost of pooled testing, but also the false-negative rate of pooled testing, which is a significant concern to public health authorities. In this study, we analyze the performance of COVID-19 pooled-testing systems with false-negative test results. To do this, we first formulate the COVID-19 pooled-testing systems with false negatives as a batch-service queuing model, and then obtain the performance measures such as the expected number of test requirements in the system, the expected number of RP-PCR tests for a test sample, the false-negative group-test rate, and the total cost per unit time, using the queueing analysis. We also present a numerical example to demonstrate the applicability of our analysis, and draw a couple of implications for COVID-19 pooled testing.

• Journal of Veterinary Clinics
• /
• v.24 no.4
• /
• pp.603-607
• /
• 2007

The sample sizes required to detect at least one chicken infectious bronchitis virus(IBV) infection at flock-level were determined using pooled samples for 48 submissions with different samples in each. A total of serum samples of 9,980 layers from Kangwon, Chungpook and Chungnam province were collected and tested hemagglutination inhibition(HI) antibody titers against IBV both individually and with pooling size of 10. Of the 48 submissions, 72.9% were required less than 5 pools to detect at least one infected pool at 95% confidence level, and the corresponding rate was 77.1% at 90% confidence level. Overall, the number of pools was decreased as the percent of positive pools increased. At two different cut-of HI titer${\geq}9\;and{\geq}10$ for individual samples the seroprevalence was 50.1% and 33.4%, respectively while 59.9% were seropositive for pooled samples at HI $titer{\geq}8$. The correlation coefficients between pooled and individual samples at each submission were 0.592(p<0.001) for HI $titer{\geq}9$ and 0.561(p<0.001) for ${\geq}10$, with common correlation coefficient of 0.576. This study indicated that pooled testing for the detection of IBV infection may be an alternative strategy when only the pooled results are of interest and the prevalence has not known exactly.

• Korean Journal of Clinical Laboratory Science
• /
• v.43 no.4
• /
• pp.133-137
• /
• 2011

The monitoring of heparin therapy is using almost aPTT assay. This study is compare to estimating aPTT therapeutic range using in vitro heparin-spiked sample and aPTT therapeutic range using in vivo heparin-treated sample. Normal pooled plasma was collected from 20 healthy representative individuals. 11 concentration of heparinized plasmas from 0 U/mL to 1.0 U/mL at intervals of 0.1 U/mL made by addition of heparin to normal pooled plasma were measured aPTT. The aPTT therapeutic range was performed through correlation analysis between heparin level 0.2 to 0.4 U/mL and aPTT. 30 plasmas from patients on heparin therapy were measured aPTT and anti-Xa activity. The aPTT therapeutic range was performed through correlation analysis between anti-Xa activity 0.3 to 0.7 U/mL and aPTT. The aPTT therapeutic range corresponded by heparin level-vs-aPTT value regression analysis was 60.7 to 102.4 seconds. The aPTT therapeutic range corresponded by anti-Xa activity-vs-aPTT value regression analysis was 85.3 to 147.5 seconds. The validation of heparin sensitivity using in-vitro heparin sample was not considered. The establishing aPTT therapeutic range is recommended anti-Xa activity using in-vivo sample.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.12
• /
• pp.5029-5034
• /
• 2014

This study aimed to summarize published epidemiological evidence for the relationship between pancreatitis and subsequent risk of pancreatic cancer (PC). We searched Medline and Embase for epidemiological studies published by February $5^{th}$, 2014 examining the risk of PC in pancreatitis patients using highly inclusive algorithms. Information about first author, year of publication, country of study, recruitment period, type of pancreatitis, study design, sample size, source of controls and attained age of subjects were extracted by two researchers and Stata 11.0 was used to perform the statistical analyses and examine publication bias. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated with the random effects model. A total of 17 articles documenting 3 cohort and 14 case-control studies containing 14,667 PC cases and 17,587 pancreatitis cases were included in this study. The pooled OR between pancreatitis and PC risk was 7.05 (95%CI: 6.42-7.75). Howeever, the pooled ORs of case-control and cohort studies were 4.62 (95%CI: 4.08-5.22) and 16.3 (95%CI: 14.3-18.6) respectively. The risk of PC was the highest in patients with chronic pancreatitis (pooled OR=10.35; 95%CI: 9.13-11.75), followed by unspecified type of pancreatitis (pooled OR=6.41; 95%CI: 4.93-8.34), both acute and chronic pancreatitis (pooled OR=6.13; 95%CI: 5.00-7.52), and acute pancreatitis (pooled OR=2.12; 95%CI: 1.59-2.83). The pooled OR of PC in pancreatitis cases diagnosed within 1 year was the highest (pooled OR=23.3; 95%CI: 14.0-38.9); and the risk in subjects diagnosed with pancreatitis for no less than 2, 5 and 10 years were 3.03 (95%CI: 2.41-3.81), 2.82 (95%CI: 2.12-3.76) and 2.25 (95%CI: 1.59-3.19) respectively. Pancreatitis, especially chronic pancreatitis, was associated with a significantly increased risk of PC; and the risk decreased with increasing duration since diagnosis of pancreatitis.

• The Journal of Asian Finance, Economics and Business
• /
• v.5 no.2
• /
• pp.5-14
• /
• 2018

This study is motivated based on concern from some renowned scholars and central bankers whom have raised the issue of the sustainability of the International Monetary System (IMS). Using the panel data set of four major international currencies, USD, JPY, EUR and GBP from 1973 to 2013 with Pooled Mean Group (PMG) estimator, to re-examine whether Triffin dilemma still exists through investigating the relationship between the reserve share, current account balance and real effective exchange rate. The evidence from the result indicates that Triffin dilemma exists only in the long run, and shows that in the long-run, current account balance is proportionate to the increased real effective exchange rate while varies inversely with the reserve shares. However, the estimation for the short-run is not significant to prove the existence of Triffin dilemma. In addition, we investigated the non-dollar panel sample and found that the international monetary system still suffers from Triffin dilemma even without the dollar. To overcome Triffin dilemma, immediate step such as having currency swap mechanism is recommended. In medium term, a multi-polar Monetary System is suggested, and in the longer time, a supranational currency will be used to replace all the currencies in the world.